ArticleDrug design, development and therapy2025
Comparison of Ciprofol, Remimazolam, and Propofol on Arrhythmia Inducibility in Pediatric Supraventricular Tachycardia: A Retrospective Study.
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advantages of Ciprofol with Special Consideration of Pediatric Anesthesia.Children (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Propofol is a commonly used intravenous anesthetic in pediatric patients. Ciprofol and remimazolam, newly approved agents, cause minimal injection pain and demonstrate stable hemodynamic characteristics. This study aimed to evaluate their effects on arrhythmia inducibility in pediatric supraventricular tachycardia (SVT). Patients and Methods: A retrospective analysis was conducted on the clinical data of pediatric patients with supraventricular tachycardia who underwent radiofrequency ablation under general anesthesia from May 2020 to June 2024. After excluding 28 cases, 173 patients were deemed eligible for analysis. According to the intravenous anesthesia drugs administered, the patients were classified into the propofol group (Group P), the ciprofol group (Group C), and the remimazolam group (Group R). The primary outcome measure was the arrhythmia inducibility, while the secondary outcome measures encompassed ablation success, extubation time, bispectral index (BIS) value, peri - operative relevant parameters, and the incidence of postoperative nausea and vomiting. Results: No significant difference was observed in the arrhythmia inducibility among the three groups (97.40% vs 95.35% vs 94.34%) (P>0.05). The secondary outcome measures in the three groups, including ablation success (P > 0.05), isoprenaline use (P > 0.05), recurrence (P > 0.05) and operation time (P > 0.05), were similar. Additionally, there was no significant difference in the incidence rates of nausea and vomiting. Excluding the baseline BIS, the Bispectral Index values of Group R were significantly higher than those of Group P and Group C at the same time point (P<0.05). Moreover, the extubation time in Group R was shorter than that in Group P and Group C. Conclusion: The effects of ciprofol and remimazolam on arrhythmia inducibility in pediatric supraventricular tachycardia were comparable to those of propofol. Both ciprofol and remimazolam are appropriate for radiofrequency ablation of supraventricular tachycardia in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.